Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Neutron activation based gamma scintigraphic evaluation of enteric-coated capsules for local treatment in colon.

Marvola T, Marvola J, Kanerva H, Ahonen A, Lindevall K, Marvola M.

Int J Pharm. 2008 Feb 12;349(1-2):24-9. Epub 2007 Aug 2.

PMID:
17869037
2.

Are chitosan formulations mucoadhesive in the human small intestine? An evaluation based on gamma scintigraphy.

Säkkinen M, Marvola J, Kanerva H, Lindevall K, Ahonen A, Marvola M.

Int J Pharm. 2006 Jan 13;307(2):285-91. Epub 2005 Nov 28.

PMID:
16310992
3.

Orally administered recombinant metallo-beta-lactamase preserves colonization resistance of piperacillin-tazobactam-treated mice.

Stiefel U, Harmoinen J, Koski P, Kääriäinen S, Wickstrand N, Lindevall K, Pultz NJ, Bonomo RA, Helfand MS, Donskey CJ.

Antimicrob Agents Chemother. 2005 Dec;49(12):5190-1. No abstract available.

4.

Neutron activation-based gamma scintigraphy in pharmacoscintigraphic evaluation of an Egalet constant-release drug delivery system.

Marvola J, Kanerva H, Slot L, Lipponen M, Kekki T, Hietanen H, Mykkänen S, Ariniemi K, Lindevall K, Marvola M.

Int J Pharm. 2004 Aug 20;281(1-2):3-10.

PMID:
15288338
5.

Gamma scintigraphic evaluation of the fate of hydroxypropyl methylcellulose capsules in the human gastrointestinal tract.

Honkanen O, Marvola J, Kanerva H, Lindevall K, Lipponen M, Kekki T, Ahonen A, Marvola M.

Eur J Pharm Sci. 2004 Apr;21(5):671-8.

PMID:
15066668
6.

Scintigraphic verification of adherence of a chitosan formulation to the human oesophagus.

Säkkinen M, Marvola J, Kanerva H, Lindevall K, Ahonen A, Marvola M.

Eur J Pharm Biopharm. 2004 Jan;57(1):145-7.

PMID:
14729090
7.

Gamma scintigraphic evaluation of the fate of microcrystalline chitosan granules in human stomach.

Säkkinen M, Marvola J, Kanerva H, Lindevall K, Lipponen M, Kekki T, Ahonen A, Marvola M.

Eur J Pharm Biopharm. 2004 Jan;57(1):133-43.

PMID:
14729089
8.

Orally administered targeted recombinant Beta-lactamase prevents ampicillin-induced selective pressure on the gut microbiota: a novel approach to reducing antimicrobial resistance.

Harmoinen J, Mentula S, Heikkilä M, van der Rest M, Rajala-Schultz PJ, Donskey CJ, Frias R, Koski P, Wickstrand N, Jousimies-Somer H, Westermarck E, Lindevall K.

Antimicrob Agents Chemother. 2004 Jan;48(1):75-9.

9.

Oral administration of beta-lactamase preserves colonization resistance of piperacillin-treated mice.

Stiefel U, Pultz NJ, Harmoinen J, Koski P, Lindevall K, Helfand MS, Donskey CJ.

J Infect Dis. 2003 Nov 15;188(10):1605-9. Epub 2003 Oct 23.

PMID:
14624388
10.

Enzymic degradation of a beta-lactam antibiotic, ampicillin, in the gut: a novel treatment modality.

Harmoinen J, Vaali K, Koski P, Syrjänen K, Laitinen O, Lindevall K, Westermarck E.

J Antimicrob Chemother. 2003 Feb;51(2):361-5.

PMID:
12562703
11.

The effect of enoxaparin in prevention of deep venous thrombosis in hip and knee surgery--a comparison with the dihydroergotamine-heparin combination.

Perhoniemi V, Vuorinen J, Myllynen P, Kivioja A, Lindevall K.

Ann Chir Gynaecol. 1996;85(4):359-63.

PMID:
9014067

Supplemental Content

Loading ...
Support Center